According to the Autoimmune Association, approximately 50 million Americans live with an autoimmune disease, yet these ...
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative ...
Genomics, a science-led biotech company using large-scale genetic information for drug discovery and development and to ...
CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasionâ„¢ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026PHILADELPHIA, April 30, 2026 ...
Autoimmune inner ear disease (AIED) is a complex condition in which the immune system aberrantly targets inner ear structures, leading to a fluctuating and often progressive sensorineural hearing loss ...
It sounds like alchemy: doctors treating rheumatoid arthritis with the beloved base metal gold. Popularized in the 1920s by French physician Jacques Forestier, injecting gold compounds became a ...
The last decade has witnessed significant developments in the understanding of the pathogenesis of alopecia areata, as well as the emergence of drugs which ...
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the ...
ERAPs (ERAP1 and ERAP2) are emerging therapeutic targets associated with multiple autoimmune diseases.Genomics will assemble the largest available genetic resource to evaluate how ERAP variants ...
Linear IgA bullous dermatosis (LABD) is an autoimmune disease that causes blisters. People with LABD can develop blisters in the skin and the mucous membranes in their mouth, genitals, and eyelids.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results